New combo therapy aims to outsmart follicular lymphoma
NCT ID NCT07555470
First seen Apr 29, 2026 · Last updated May 22, 2026 · Updated 4 times
Summary
This study tests two drugs, mosunetuzumab and zeprumetostat, together for people with follicular lymphoma, a type of blood cancer. About 80 adults will join, including those newly diagnosed and those whose cancer returned. The goal is to see if the combination can shrink tumors and keep the cancer from coming back longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
Tianjin, China
Contact
Conditions
Explore the condition pages connected to this study.